美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Nasdaq Biotechnology ETF

34.82

+0.34801.01%

盤後：34.820.00000.00%19:30 EDT

成交量：1.41萬

成交額：48.94萬

市值：9,679.96萬

市盈率：- -

高：34.92

開：34.52

低：34.42

收：34.47

52周最高：36.84

52周最低：23.42

股本：278.00萬

流通股本：278.00萬

量比：0.80

換手率：0.51%

股息：0.26

股息率：0.74%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

高盛9月「確信名單」更新：美股納入福泰製藥歐股力推萊茵、Adyen和塔蘭克斯

中國醫藥巨頭與美國政府達成協議：一抗癌藥降價，承諾未來全部創新藥均執行「最惠國價格」公司回應：該協議是自願達成的

這家「最會賺錢的創新藥第一股」，貝達藥業赴港IPO，未來懸念重重……

年費用超47萬美元，「癌王」新藥在美獲批國產靶向藥還要等多久？

每日经济新闻

英國監管機構因數據不可靠，暫停安進公司Tavneos用於新患者

石藥集團(01093.HK)：SYH2056片用於治療抑鬱症的I期臨床試驗在中國正式啓動

英國藥品與健康產品管理局：通知上市許可持有方，自9月1日起暫停新患者使用、供應及銷售Avacopan Vifor

智飛生物(300122.SZ)：凍幹人用狂犬病疫苗(ZFB-3細胞)臨床試驗申請獲受理

中關村(000931.SZ)下屬公司鹽酸哌甲酯緩釋咀嚼片獲批開展臨床試驗

智飛生物：智飛龍科馬疫苗臨床試驗申請獲受理，60日內可開展

中關村：北京華素40mg鹽酸哌甲酯緩釋咀嚼片獲准開展臨床試驗

2026創新藥出海：百濟領跑行業榮昌、恒瑞們靠BD緊隨其後君實、康方短板明顯出海步履遲緩

新版基藥目錄正式施行!BD出海勢頭延續創新藥有望迎「下沉+出海」雙輪驅動

諾華製藥(NVS.US)神經免疫管線「悲喜交加」：患者死亡致CAR-T臨床試驗暫停 MS口服藥後期試驗告捷

凱萊英旗下公司入選上海市生物醫藥研發和檢測用物品進口試點企業目錄

上海市商務委等六部門和單位關於公布上海市生物醫藥研發和檢測用物品進口試點企業目錄的通知

吉倫泰研製的靶向整合素αvβ3治療核藥獲得國家藥監局臨床試驗批件

百濟神州：PD-1抗癌藥降價加入美國公共醫療保險計劃今後上市創新藥均將執行最惠國定價

每日经济新闻

雙輪驅動表現亮眼創新藥企需警惕業績波動風險

2026版國家基藥目錄今起施行：4款國產創新藥納入

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/IBBQ/news?page=10"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.82,"timestamp":1789416000000,"preClose":34.472,"halted":0,"volume":14094,"hourTrading":{"tag":"盘后","latestPrice":34.82,"preClose":34.82,"latestTime":"19:30 EDT","volume":36,"amount":1244.0123,"timestamp":1789428600873,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01009514968670222,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"已收盤","change":0.348,"latestTime":"09-14 16:00:00 EDT","open":34.52,"high":34.92,"low":34.42,"amount":489401.81775,"amplitude":0.014505,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":34.472,"sharesOutstanding":2520001,"nav":34.43989,"aum":95742928.63989,"dividendRate":0.007412,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":34.82,"preClose":34.82,"latestTime":"19:30 EDT","volume":36,"amount":1244.0123,"timestamp":1789428600873,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.801497,"impliedVol":0.1149,"impliedVolPercentile":0.4861},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.801497,"shares":2780001,"dividePrice":0.2581,"high":34.92,"amplitude":0.014505,"preClose":34.472,"low":34.42,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.82,"eps":0,"divideRate":0.007412,"volume":14094,"delay":0,"ttmEps":0,"open":34.52,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":36.05,"twentyDayClose":33.8122,"sixtyDayClose":29.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:10,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664891705","title":"高盛9月「確信名單」更新：美股納入福泰製藥 歐股力推萊茵、Adyen和塔蘭克斯","url":"https://stock-news.laohu8.com/highlight/detail?id=2664891705","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664891705?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 15:20","pubTimestamp":1788333621,"startTime":"0","endTime":"0","summary":"进入秋季，高盛对其美国及欧洲市场的“确信名单”进行了更新，为投资者指明当前最看好的股票方向。本次调整中，美国名单新增一只大型生物科技股，欧洲名单则迎来三家新面孔。美国名单：新增福泰制药，移除盈透证券在美国市场，高盛将 $福泰制药$纳入确信名单，同时移除了 $盈透证券$，调整后名单保留23只股票。高盛还表示，塔兰克斯的国际零售业务是被低估的增长引擎。","market":"us","thumbnail":"https://static.tigerbbs.com/1b3684302211042d481cacf9066fbcca","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/1b3684302211042d481cacf9066fbcca"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490866.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0034235188.USD","XYZ","IBBQ","CRNX","BIB","LU0345770993.USD","LU2471134523.USD","GNMX","LU1868836757.USD","LU2236285917.USD","COP","IE00B19Z3581.USD","MSFX","UNHW","LU2362541273.HKD","XYZG","LU0106831901.USD","DAL","LU2456880835.USD","IBB","BK4504","GSX","LU2471134796.USD","UNHG","IBKR","IE00BFTCPJ56.SGD","BK4567","LU1868837136.USD","LU1868837300.USD","IE00B2B36J28.USD","LU2471134952.CNY","PBE","BK4533","LU0109394709.USD","SG9999001176.USD","LU2471134879.HKD","MSFU","EL","SG9999001176.SGD","BBH","LU2468319806.SGD","IE00BJT1NW94.SGD","MSFL","UN","MSFD","LU1585245621.USD","MSFY","IE0002270589.USD","MSFC","XYZY","MSFW","IE0004091025.USD","LU0889565916.HKD","VXUS","LU2265009873.SGD","VRTX","LU2417539215.USD","IE00BFXG1179.USD","BK4585","IEV","TBXU","LU2237443549.SGD","BK4532","VGK","MSFT","UNH","LU0432979614.USD","LU2750360641.GBP","IDNA","MSFO","UNHU","WFC","LU1069344957.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664891978","title":"中國醫藥巨頭與美國政府達成協議：一抗癌藥降價，承諾未來全部創新藥均執行「最惠國價格」 公司回應：該協議是自願達成的","url":"https://stock-news.laohu8.com/highlight/detail?id=2664891978","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664891978?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 15:09","pubTimestamp":1788332941,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CANC","LNGR","MEDX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664867024","title":"這家「最會賺錢的創新藥第一股」，貝達藥業赴港IPO，未來懸念重重……","url":"https://stock-news.laohu8.com/highlight/detail?id=2664867024","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664867024?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 08:53","pubTimestamp":1788310380,"startTime":"0","endTime":"0","summary":"老药的余晖埃克替尼之于贝达药业，是起点，也是命脉。仿制药上市后几乎必然以低价渗透市场，一旦竞争充分，埃克替尼或将被迫卷入国家或地区集中带量采购，面临进一步的降价压力。招股书承认，协议项下合计人民币1.8亿元的若干监管里程碑付款已被触发，并成为公司的应付款项。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-02/doc-iniqkvce1333036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["KCE","06978","FRHC","IBBQ","IPOS","BK1161","BK0239","BK4127","BK1574","BK0060","159992","LNGR","MEDX","REDS","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664854547","title":"年費用超47萬美元，「癌王」新藥在美獲批 國產靶向藥還要等多久？","url":"https://stock-news.laohu8.com/highlight/detail?id=2664854547","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664854547?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 21:20","pubTimestamp":1788268838,"startTime":"0","endTime":"0","summary":"按照国际癌症研究署预测，2030年，死于胰腺癌将成为全球第二大癌症死亡原因。但在2026年8月，“癌王”的治疗迎来了历史性突破。近日，美国食品药品监督管理局正式批准RevolutionMedicines（一家美国生物科技公司）开发的每日口服RAS抑制剂（靶向RAS基因突变或其下游信号通路的新型抗癌药）Daraxonrasib，用于治疗经治的胰腺导管腺癌患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609013861719398.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609013861719398.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","LU1854104046.USD","LU0124384867.USD","LU0724618433.USD","IE00BD6J9T35.USD","ONG","LU0348723411.USD","LU1978683503.SGD","BK4141","LU1861220033.SGD","IBBQ","LU2298322129.HKD","BK4588","IE00BZ199S13.USD","LU1854103824.USD","ON","LU1548497426.USD","LU2360107325.USD","LU1861215975.USD","BK4512","LU1720051108.HKD","ONX","BK4605","IE00BFMHRM44.USD","LU2357305700.SGD","LU1861219969.SGD","LU1983260115.SGD","LU1720051017.SGD","LU1861214812.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664347855","title":"英國監管機構因數據不可靠，暫停安進公司Tavneos用於新患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2664347855","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664347855?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 19:15","pubTimestamp":1788261324,"startTime":"0","endTime":"0","summary":"英国监管机构因数据不可靠，暂停安进公司Tavneos用于新患者路透9月1日-英国药品监管机构周二暂停了安进公司旗下AMGN.O研发的罕见病药物Tavneos对新患者的使用和销售，称支持该药获批的主要研究结果不可靠。监管机构表示，由于主要临床试验的数据不可靠，该研究已无法证明该药有效，也无法证明其益处大于风险。Tavneos由ChemoCentryx公司研发，安进公司于2022年以37亿美元收购了该公司。欧洲委员会于8月撤销了Tavneos的批准，此前监管机构发现其关键试验数据不可靠。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nL4T44T10B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","PBE","BK4566","IE00BJJMRZ35.SGD","LU2089984988.USD","BK7501","BBH","LU0122379950.USD","TBXU","LU1057294990.SGD","BK7511","BK4588","AMGN","BK7508","LU2468319806.SGD","SG9999001440.SGD","IBB","LU2242646821.SGD","LU2242652126.USD","LU0320765992.SGD","PJP","BK7067","BK4139","IE00B2B36J28.USD","LU0109394709.USD","IE0002141913.USD","LU2112291526.USD","CSL.AU","LU0889565916.HKD","BK4581","LU1983299246.USD","BK4533","BK4585","LU1061106388.HKD","LU1571399168.USD","IBBQ","LU0058720904.USD","LU0868494617.USD","BIB","BK4599","BK4534","LU1023059063.AUD","IE00B4R5TH58.HKD","IE0009355771.USD","LU0289739699.SGD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664355858","title":"石藥集團(01093.HK)：SYH2056片用於治療抑鬱症的I期臨床試驗在中國正式啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2664355858","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664355858?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 18:12","pubTimestamp":1788257547,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","PSYK","MDTX","BMED","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148791645","title":"英國藥品與健康產品管理局：通知上市許可持有方，自9月1日起暫停新患者使用、供應及銷售Avacopan Vifor","url":"https://stock-news.laohu8.com/highlight/detail?id=1148791645","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148791645?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 17:35","pubTimestamp":1788255329,"startTime":"0","endTime":"0","summary":"英国药品与健康产品管理局（MHRA）已正式告知上市许可持有方，关于暂停Avacopan Vifor用于新患者的使用、供应及销售的相关决定。该措施自9月1日起生效。此番调整涉及该药物的市场流通环节，意在规范其临床应用范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","BK4581","PJP","BK4599","LU1571399168.USD","TBXU","IE0002141913.USD","BBH","LU0889565916.HKD","LU2468319806.SGD","IBB","BK4585","PBE","LU0868494617.USD","SG9999001440.SGD","LU1983299246.USD","LU1061106388.HKD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU2242646821.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4534","LU2242652126.USD","LU2112291526.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","BK4139","LU1023059063.AUD","IE00BJT1NW94.SGD","IBBQ","LU2089984988.USD","BK4588","AMGN","LU0320765992.SGD","BIB","BK4566","LU0122379950.USD","BK4533","LU0058720904.USD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664832774","title":"智飛生物(300122.SZ)：凍幹人用狂犬病疫苗(ZFB-3細胞)臨床試驗申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664832774","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664832774?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 17:05","pubTimestamp":1788253557,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物(300122.SZ)发布公告，公司于近日获悉，由全资子公司安徽智飞龙科马生物制药有限公司研发的冻干人用狂犬病疫苗(ZFB-3细胞)获得国家药品监督管理局药物临床试验申请受理通知书。该药品用于预防狂犬病。通过接种该疫苗，可剌激机体产生抗狂犬病病毒的免疫力。该药品以公司自主研制的人二倍体细胞株(ZFB-3细胞)作为生产基质，与动物源性细胞狂犬病疫苗相比，理论上局部和全身不良反应发生率更小，且无致瘤性风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490370.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","LU1064130708.USD","LU2148510915.USD","300122","BK0188","LU1328615791.USD","PSYK","LU2580892789.USD","BK0239","BK0077","BK0196","BMED","IBBJ","IBBQ","LU2580892862.HKD","LU1064131003.USD","BK0046","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664083225","title":"中關村(000931.SZ)下屬公司鹽酸哌甲酯緩釋咀嚼片獲批開展臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2664083225","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664083225?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 16:59","pubTimestamp":1788253144,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中关村(000931.SZ)发布公告，公司下属公司北京华素制药股份有限公司(简称：北京华素)于近日收到国家药品监督管理局核准签发的盐酸哌甲酯缓释咀嚼片(规格：40mg)《药物临床试验批准通知书》。该药品拟开展用于注意缺陷多动障碍(ADHD)的临床试验。截至目前，中国境内仅1家原研进口获批上市，北京华素为国内第一家获批本品仿制药临床试验许可的企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BMED","BK0178","BK0075","000931","IBBJ","BK0239","IBBQ","MDTX","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664083291","title":"智飛生物：智飛龍科馬疫苗臨床試驗申請獲受理，60日內可開展","url":"https://stock-news.laohu8.com/highlight/detail?id=2664083291","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664083291?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 16:53","pubTimestamp":1788252835,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","IBBQ","BMED","PRTO","PSYK","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664329148","title":"中關村：北京華素40mg鹽酸哌甲酯緩釋咀嚼片獲准開展臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2664329148","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664329148?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 16:53","pubTimestamp":1788252832,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","BMED","PSYK","IBBJ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664832570","title":"2026創新藥出海：百濟領跑行業 榮昌、恒瑞們靠BD緊隨其後 君實、康方短板明顯出海步履遲緩","url":"https://stock-news.laohu8.com/highlight/detail?id=2664832570","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664832570?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 16:46","pubTimestamp":1788252360,"startTime":"0","endTime":"0","summary":"2026年上半年，中国创新药出海交出了一份分裂感极强的答卷。百济神州扛起海外自主销售大旗 荣昌、石药靠技术授权跻身第一梯队从BD交易数据看，2026年上半年，中国创新药出海迎来黄金时代。但2026年半年报显示，公司上半年授权费收入仅3.10亿元，同比下降53.4%。简单测算，三笔交易合计22亿美元首付款，截至2026年6月末，确认计入利润表的比例不足5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-01/doc-iniqihzw1576056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","BK1574","IBBQ","BK1161","MEDX","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664834396","title":"新版基藥目錄正式施行!BD出海勢頭延續 創新藥有望迎「下沉+出海」雙輪驅動","url":"https://stock-news.laohu8.com/highlight/detail?id=2664834396","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664834396?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 16:02","pubTimestamp":1788249750,"startTime":"0","endTime":"0","summary":"　　9月1日，由国家卫生健康委、国家中医药局、国家疾控局三部门联合发布的2026版《国家基本药物目录》正式施行。时隔8年，基药目录再次迎来重磅扩容。　　在常规药品的扩容之外，新版基药目录最令市场瞩目的变化，是对创新药的大规模“敞开大门”。　　此外8月，中国创新药BD出海势头延续。大部分药企认为，进入基药目录有利于相关产品放量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangceping/20260901/32356433.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159992","BK1574","MEDX","IBBQ","06978","LNGR","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664831619","title":"諾華製藥(NVS.US)神經免疫管線「悲喜交加」：患者死亡致CAR-T臨床試驗暫停 MS口服藥後期試驗告捷","url":"https://stock-news.laohu8.com/highlight/detail?id=2664831619","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664831619?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 15:40","pubTimestamp":1788248407,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华制药在神经与自身免疫领域迎来“冰火两重天”：公司因三名患者死亡紧急叫停八项CAR-T疗法临床试验;不过，其多发性硬化症口服药remibrutinib在后期临床试验中取得积极结果。CAR-T试验紧急暂停诺华制药在8月底暂停了八项针对自身免疫和神经系统疾病的实验性疗法临床试验，此前有三名患者死亡。诺华制药发言人表示，公司正在“对所观察到的安全事件进行全面审查”，并将这种致命免疫反应描述为CAR-T疗法中已知的安全风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BFTCPJ56.SGD","MDTX","BK1574","IE00BJJMRZ35.SGD","BK4578","BMED","BK4588","NVS","BK4007","IBBJ","LU0320765489.SGD","IE00B2B36J28.USD","IE0002141913.USD","BK1191","BK4585","LU0208291251.USD","LU0070302665.USD","IBBQ","01477","MEDX","PPH","PSYK","LU0211331839.USD","BK4532","IE00B4R5TH58.HKD","IE0009355771.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664383627","title":"凱萊英旗下公司入選上海市生物醫藥研發和檢測用物品進口試點企業目錄","url":"https://stock-news.laohu8.com/highlight/detail?id=2664383627","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664383627?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 15:03","pubTimestamp":1788246222,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XBIX","BBC","RND","IBBQ","WRND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664836502","title":"上海 市商務委等六部門和單位關於公布上海市生物醫藥研發和檢測用物品進口試點企業目錄的通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2664836502","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664836502?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 14:44","pubTimestamp":1788245063,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XBIX","WRND","IBBQ","BBC","RND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664882342","title":"吉倫泰研製的靶向整合素αvβ3治療核藥獲得國家藥監局臨床試驗批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2664882342","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664882342?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 09:52","pubTimestamp":1788227549,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","MDTX","PSYK","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664026884","title":"百濟神州：PD-1抗癌藥降價加入美國公共醫療保險計劃 今後上市創新藥均將執行最惠國定價","url":"https://stock-news.laohu8.com/highlight/detail?id=2664026884","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664026884?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 09:36","pubTimestamp":1788226577,"startTime":"0","endTime":"0","summary":"美国当地时间8月31日，美国总统特朗普宣布与9家制药企业达成全新协议，为美国民众下调处方药价格，药价对标其他发达国家的最低采购价，即“最惠国（MFN）价格”，其中包括国内创新药龙头百济神州。9月1日，百济神州对《每日经济新闻》记者表示，根据协议，百济神州将通过Medicaid项目，以约定的价格向符合条件的患者提供替雷利珠单抗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609013861069086.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609013861069086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","IPOS","LU0588546209.SGD","ONC","BK1583","BK4139","LABU","BK4581","BK1161","CANC","IBBQ","LU1719994722.HKD","LU1770034418.SGD","LU2328871848.SGD","06160","LU1251922891.USD","BK0239","BK4588","06978","MEDX","BK1500","XBI","LU1169590202.USD","LU1969619763.USD","LNGR","159992","LU0828237510.HKD","LU1169589451.USD","BK1588","KURE","BK1574","LU0228659784.USD","688235","XLV","PD","BK4023","LU0307460666.USD","BK4526","LU1303224171.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664688645","title":"雙輪驅動表現亮眼 創新藥企需警惕業績波動風險","url":"https://stock-news.laohu8.com/highlight/detail?id=2664688645","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664688645?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 07:22","pubTimestamp":1788218536,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LNGR","IBBQ","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664886109","title":"2026版國家基藥目錄今起施行：4款國產創新藥納入","url":"https://stock-news.laohu8.com/highlight/detail?id=2664886109","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664886109?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 07:17","pubTimestamp":1788218277,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","LNGR","MEDX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":10,"totalSize":201,"code":"91000000","status":"200"}]}}